The impact of prenatal diagnosis on neural tube defect [NTD] pregnancy versus birth incidence in British Columbia

• Autorzy: Van Allen M I , Boyle E , Thiessen P , McFadden D , Cochrane D , Chambers G K , Langlois S , Stathers P , Irwin B , Cairns E , MacLeod P , Delisle M F , Uh S H
• Języki publikacji: EN

Abstrakty

EN

The birth incidence of neural tube defect (NTD) cases in British Columbia (B.C.), and elsewhere in North America, is reported to be declining. This decline is being attributed to folic acid (FA) supplementation and food fortification, but 2nd trimester prenatal screening of pregnancies for NTDs and other congenital anomalies has increased during this timeframe, as well. This descriptive, population-based study evaluates the impact of prenatal screening of NTD-affected pregnancies on (1) pregnancy outcome and (2) reporting of NTD births to the provincial Health Status Registry (B.C.H.S.R.); and it assesses (3) the use of periconceptional FA supplementation. NTD cases were ascertained from medical records of health centres providing care to families with NTD-affected pregnancies and newborns; and from NTD cases reported to the B.C.H.S.R. In 1997-1999, the B.C.H.S.R. published a NTD incidence of 0.77/1000. In this study, 151 NTD-affected pregnancies were identified, with an incidence of 1.16/1000. Partial Reporting of induced abortions in a NTD incidence 45.5% low than the actual incidence. Medical records were available for review on 144/151 pregnancies. Prenatal screening identified 86.1% (124/144) of NTD-affected pregnancies, with 72.6% (90/124) resulting in pregnancy termination, and 27.4% (34/124) continuing to term. Use of FA supplementation in the periconceptional period was recorded in 36.4% of pregnancies (39/107). Thus in B.C. the decline in the NTD incidence is due predominantly to pregnancy terminations following prenatal diagnosis, which reduces the NTD incidence by 60%, from 1.16/1000 to 0.47/1000. Continued efforts for primary and the option of secondary prevention of NTDs are recommended in order to improve newborn health in B.C. and elsewhere. These interventions need to be monitored, however, for optimal health care planning.

Słowa kluczowe

EN

prevention; pregnancy; birth defect registry; prenatal diagnosis; genetics; newborn incidence; British Columbia; folic acid; neural tube defect; birth incidence

• Wydawca: -
• Czasopismo: Journal of Applied Genetics
• Rocznik: 2006
• Tom: 47
• Numer: 2
• Opis fizyczny: p.151-158,ref.

Twórcy

autor

Van Allen M I

• Department of Medical Genetics, University of British Columbia, C234-4500 Oak Street, Vancouver, B.C., Canada V6H 3NI, USA

autor

Boyle E

• Department of Medical Genetics, University of British Columbia, C234-4500 Oak Street, Vancouver, B.C., Canada V6H 3NI, USA

autor

Thiessen P

• Department of Pediatrics, University of British Columbia, C234-4500 Oak Street, Vancouver, B.C., Canada V6H 3NI, USA

autor

McFadden D

• Department of Pathology, University of British Columbia, C234-4500 Oak Street, Vancouver, B.C., Canada V6H 3NI, USA

autor

Cochrane D

• Department of Surgery, University of British Columbia, C234-4500 Oak Street, Vancouver, B.C., Canada V6H 3NI, USA

autor

Chambers G K

• Department of Family Medicine, University of British Columbia, C234-4500 Oak Street, Vancouver, B.C., Canada V6H 3NI, USA

autor

Langlois S

• Department of Medical Genetics, University of British Columbia, C234-4500 Oak Street, Vancouver, B.C., Canada V6H 3NI, USA

autor

Stathers P

• Department of Medical Genetics, University of British Columbia, C234-4500 Oak Street, Vancouver, B.C., Canada V6H 3NI, USA

autor

Irwin B

• Department of Pediatrics, University of British Columbia, C234-4500 Oak Street, Vancouver, B.C., Canada V6H 3NI, USA

autor

Cairns E

• Department of Medical Genetics, University of British Columbia, C234-4500 Oak Street, Vancouver, B.C., Canada V6H 3NI, USA

autor

MacLeod P

• Department of Medical Genetics, Victoria general Hospital, Victoria

autor

Delisle M F

• Department of Perinatology, University of British Columbia, C234-4500 Oak Street, Vancouver, B.C., Canada V6H 3NI, USA

autor

Uh S H

• B.C. Health Status Registry, Victoria, British Columbia, USA

Bibliografia

• Allen WP, Stevenson RE, Thompson SJ, Dean JH, 1996. The impact of prenatal diagnosis on NTD surveillance. Prenatal Diagnosis 16: 531-535.
• Berry RJ, Li Z, Erickson JD, et al. 1999. Prevention of neural-tube defects with folic acid in China. China-U.S. Collaborative Project for Neural Tube Defect Prevention. N Engl J Med 341: 1485-1490. (Erratum in: N Engl J Med, 1999. 341: 1864).
• Brent RL, Oakley GP, Mattison Dr. 2000. The unnecessary epidemic of folic acid-preventable spina bifida and anencephaly. Pediatrics 106: 825-827.
• Castilla EE, Orioli IM, Lopez-Camelo JS, et al. 2003. Preliminary data on changes in neural tube defect prevalence rates after folic acid fortification in South America. Am J Med Gen 123A: 123-128.
• Centers for Disease Control and Prevention, 1992. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR 38: 264-267.
• Centers for Disease Control and Prevention, 2005. Spina bifida and anencephaly before and after folic acid mandate - United States, 1995-1996 and 1999-2000. MMWR 53: 362-365.
• Chambers K, Popkin J, Arnold W, Irwin B, Hall JG, 1994. Neural tube defects in British Columbia. Lancet 343: 489-490.
• Cochrane DD, Wilson RD, Steinbok P, et al. 1996. Prenatal spinal evaluation and functional outcome of patients born with myelomeningocele: Information for improved prenatal counselling and outcome prediction. Fetal Diagn Ther 11: 159-186.
• Cuckle H, Wald N, 1987. The impact of screening for open neural tube defects in England and Wales. Prenatal Diagnosis 7: 91-99.
• Czeizel AE, Dudas I, 1992. Prevention of the first occurrence of neural tube defects by periconceptional vitamin supplementation. N Eng J Med 327: 1832-1835.
• De Wals P, Rusen ID, Lee NS, et al. 2003. Trend in prevalence of neural tube defects in Quebec. Birth Defects Research (Part A) 67: 919-923.
• Ethen MK, Canfield MA, 2002. Impact of including elective pregnancy terminations before 20 weeks gestation on the birth defect rates. Teratology 66 (supplement 1): 32-35.
• Feldkamp M, Friedrichs M, Carey JC, 2002. Decreasing prevalence of neural tube defects in Utah, 1985-2000. Teratology 66(supplement 1): 23-28.
• French, Levy-Milne, 2000. Folate intakes and knowledge of women of childbearing age. The status in British Columbia. MSc thesis, Vancouver, UBC, August 2000.
• Gallop Organization-March of Dimes, 1997. Preparing for pregnancy II. March of Dimes, Birth Defects Foundation. White Plains, NY.
• Gucciardi E, Pietrusiak M-A, Reynolds DL, Rouleau J, 2002. Incidence of neural tube defects in Ontario. 1986-1999. CMAJ 167: 237-240.
• Hall JG, Friedman JM, Keena BA, et al. 1988. Clinical genetics and epidemiologic factors in neural tube defects. Am J Hum Genet 43: 827-837.
• Health Canada, 2002. Congenital anomalies in Canada - a perinatal health report, 2002. Ottawa: Minister of Public Works and Government Services Canada, Ottawa.
• Health Status Registry, 1999. Selected vital statistics and health status indicators. Annual report 1999. Victoria, B.C.: Division of Vital Statistics.
• Honein MA, Paulozzi LJ, Mathews TJ, et al. 2001. Impact of folic acid fortification on the US food supply on the occurrence of neural tube defects. JAMA 285: 2981-2986.
• Lowry B, 2001. Alberta Congenital Anomaly Surveillance System. Fifth Report, 1980-1998. Division of Vital Statistics, Alberta Registries, Edmonton, Alberta.
• Mills JL, Rhoads GG, Simpson JL, et al. 1989. The absence of a relation between the periconceptional use of vitamins and neural-tube defects. N Engl J Med 321:430-435.
• Mills JL, Signore C, 2004. Neural tube defect rates before and after food fortification with folic acid. Birth Defects Research (Part A) 70: 844-845.
• Morin VI, Mondor M, Wilson RD, 2001. Knowledge on periconceptional use of folic acid in women of British Columbia. Fetal Diagn Ther 16: 111-115.
• MRC Vitamin Study Research Group, 1991. Prevention of neural tube defects: results of the Medical Research Vitamin Study. Lancet 338: 131-137.
• Oakly GP Jr, 1993. Folic acid preventable spina bifida and anencephaly. JAMA 269: 1292-1293.
• Oakley GP Jr, 2002. Inertia on folic acid fortification: public health malpractice. Teratology 66: 44-54.
• Oakley GP Jr, Bell KN, Weber MB, 2004. Recommendations for accelerating global action to prevent folic acid-preventable birth defects and other folate-deficiency diseases: Meeting of experts on preventing folic acid-preventable neural tube defects. Birth Defects Research (Part A) 70:835-837.
• Persad VL, Van den Hoff MC, Dube JM, Zimmer P, 2002. Incidence of open neural tube defects in Nova Scotia after folic acid fortification. CMAJ 167: 241-245.
• Roberts HE, Moore CA, Fernhoff PM, Cragan JD, Khoury MJ, 1994. The impact of prenatal diagnosis on the birth prevalence of neural tube defects, Metropolitan Atlanta, 1990-1991. Teratology 49: 386.
• Rosano A, Smithells D, Cacciani L, et al. 1999. Time trends in neural tube defects prevalence in relation to preventive strategies: An international study. J Epidemiol Community Health 53: 630-635.
• State Birth Defects Surveillance Programs Directory, 2002. Neural tube defects (NTDs) rates, 1995-1999. Teratology 66: 59-128.
• Stevenson RE, Allen WP, Pai GS, et al. 2000. Decline in prevalence of neural tube defects in a high-risk region of the United States. Pediatrics 106: 677-682.
• Van Allen MI, Fraser FC, Dallaire L, et al. 1993. Recommendations on the use of folic acid supplementation to prevent the recurrence of neural tube defects. Can Med Assoc J 149: 1239-1243.
• Velie EM, Shaw GM, 1996. Impact of prenatal diagnosis and elective termination on prevalence and risk estimates of neural tube defects in California, 1989-1991. Am J Epidemiol 144: 473-479.
• Wilson RD, Van Allen MI, 1993. The use of folic acid for prevention of neural tube defects. J Soc Obstet Gynaecol Can 15 (March suppl): 41-46.
• Williams LJ, Mai CT, Edmonds LD, et al. 2002. Prevalence of spina bifida and anencephaly during the transition to mandatory folic acid fortification in the United States. Teratology 66: 33-39.